There are a number of investors who bought in waiting for the trial data and were selling on the release. The data was 50/50. Squamous a no-go. Not the end of the world since non-squamous is about 75% of cases. To be fair you said three months ago that CADL would be $50 in 25.

This happens. Study relatively successful but means more studies meaning more money spent. I sort of don't buy the stability excuse for them not being able to apply to the FDA before 2026. Don't typically hear that with other drugs. But I am not giving up on them.

Since you are pushing their success out to 2026, it is within the realm of possibility (not probable but possible) that Amarin's stock price multiplies almost as fast as CADL's.

This is a BofA analyst rec today on CADL:

"Alec Stranahan has given his Buy rating due to a combination of factors including the promising survival data from Candel Therapeutics' lead cancer vaccine, CAN-2409, in non-small cell lung cancer (NSCLC). The updated phase 2a trial results show significant improvements in overall survival, particularly in the non-squamous patient population, which suggests a strong potential for differentiation from the standard of care. Additionally, the recent partnership with IDEA Pharma is
expected to accelerate commercialization efforts, enhancing the company's ability to bring CAN-
2409 to market more swiftly and effectively. Furthermore, the company's strategic focus on non-squamous histology patients, who have shown
particularly strong responses, aligns with the observed biomarker responses and survival benefits. While additional financing may be needed for larger trials and regulatory filings, the positive safety profile and systemic anti-tumor responses observed in trials support the potential for CAN-2409's success across multiple indications. These factors, combined with the potential value from CAN-
3110, contribute to the positive outlook and Buy rating for Candel Therapeutics' stock."

Sleven, this management group since taking over has not given me any reason to vote for them to answer your question. More about that at the end of this post.

As far as sales you can see them here:

https://www.secform4.com/13dg-history/1577524-1.html

And of course there had to be sales to get the cost avg down to 1.29. Look at all these purchases well above that price:
https://www.secform4.com/13dg/1577524/0000899140-22-000088.html

Now, I think more importantly than simply voting against this group, is what is installed instead? If we put in another group of neophytes, then there is a learning curve, etc., and not enough time to turn the ship around. What we need is an activist (yes I can hear the screams from the board now) that can lock us into a strategic review (obviously to arrange a sale) or set up an auction of the company. Or someone who doesn't have to learn the ropes and can resurrect our prospects. I don't see or have heard of anyone on the horizon clamoring to be elected to the Amarin board. If anyone knows of such, I would be interested in hearing their objectives. So I don't see myself giving the current group my vote but will there be anyone else to vote for or do I just abstain/withhold?

Wondering.  Are you saying that based on the trading action this week/month or something else?

Thanks for your thoughts on this.  So it would extend the time frame for readout and cost more money.  Wish thry could sell their other asset. 

Good luck to both of us. 

Raggy definitely saw the news on CADL, but dumbfounded at the stock price.  Shoukd have sold at 14.  Guess since these trials were successful it means more trials and more expenses.  
As far as Amarin, I took that threat of tariffs against the Irish companies as not specifically related to API but some idea in his head that these companies were making money off of Americans but not paying tax here.  Hard to tell since most of what is spewed is devoid of much detail.  If Amarin can stop the losses, it can still be a safe investment.  But if course most of us long termers are looking to recoup some our paper losses here so we need more than safe.  
Why do you think after all this good news CADL is at 7.50 when it was also 14 a couple of months ago?

Anyone know if Amarin pays (well let's say files since they don't make a profit) U.S Income Tax.  
Wondering since we are pondering how tariffs might affect Generics and their ability to sell GV here in the States.  When the Irish leader was here at the White House he heard an earful about Irish drug companies. This is what the President said:
""When the pharmaceutical companies started to go to Ireland, I would have said that’s OK, if you want to go to Ireland. I think that’s great. But if you want to sell anything into the United States, I’m going to put a 200% tariff on you so you’re never going to be able to sell anything into the United States," Trump said. "You know what they would have done? They would have stayed here." 
Now I realize he was talking about the past but I understand tariffs on the EU would also entail Ireland.  I realize too that this is different than tariffs based on source of API, but if Trump's thinking is still as in his quote he just may be pissed that Irish companies are selling here but only paying tax in Ireland so who knows if Amarin could be affected.  Hopefully not but difficult to count on anything from day to day.  

Reminds me of the Pied Piper.  And everyone in the Administration in a trance simply following along.  Thanks for the heads up on the TikTok announcement.  I may still repurchase those shares I sold as the market clearly can't get a handle on the on again off again tariffs.  I was somehow hoping that we would rally into the second or third week of April and that I could be earlier than the herd to do the sell in May routine, and then be ready to buy big in October.  But you know what they say about best laid plans.  

Who might not......

Was only trying to point out to those you might not understand the low cost basis that Sarissa already booked a loss on the higher priced shares. 

But there is also another way of looking at this. If you and have 1000 shares purchased at say $10, and then we but 1000 more at $5, our cost basis drops to $7.50 a share.  But when we look at Denner's cost basis now at $1whatever. NOT really.  He sold and booked losses on his higher priced shares.  His new cost basis only represents the newly purchased shares as he has jettisoned his higher priced ones.  So when people think that he could sell the company for say $2 a share and be way ahead because his cost basis is $1whatever, that does not take into consideration the money he lost on his higher priced shares that he apparently has already sold.  We on the other have not sold anything (some of us haven't and so our cost basis looks higher than his now, but not really.  

Market taking a hit from copper tariff announcement.  Amarin hanging there.  

Thanks for clearing that up for me Jroon. 

Not sure how all that works with these hedge fund type things. But if I have two accounts, and sell a stock in one creating a loss, but immediately (with 30 days either way) repurchase the stock in another account, the IRS considers that a wash sale and I don't get the benefit of claiming a loss on the sold shares. So not sure how Denner works this. Does he not own the other accounts?

I notice that Mark DiPaolo is not running for the board at this coming meeting. Does it mean anything?

You are correct North.  It should be NVS.  They actually should have jumped on Amarin when their mixed omega product failed.

Sounds like a way NVO can get their hands on V, without automatically burdening themselves with all the mess with litigation and Generics.  If that situation ultimately clears itself up they could then come.  Kind of like a CVR in some sense.  The big questions are:  are they interested and will they move on it. 

North, I am also invested in AVXL. Do you think any potential buyout there will wait to see what the EMA does in terms of approval first?

Last sentence makes wonder if Nissen is pissed that the Cleveland Clinic has given grants to Dr. Mason. Thanks for posting.  Have a good workweek tomorrow

Just sold half. Not a home run but need to take some singkes, doubles, and triples. 

And, not to mention that if things continue as they are (very slow growth) management may decide that they want to acquire another asset (they have mentioned having some thought towards that) or to raise more funds to try various other means to boost business (more salespeople in the EU or advertising here or even figure they need another trial to prove Nissen's gang wrong). Who knows. But with only 20 million shares it gives them a lot of runway.

I am sticking it out here past the RS. Still worried shorts may drive this lower after RS but I do buy the argument that it is so undervalued it would not make much sense for that to happen (of course we know that market is not always rational). However, if there is any movement towards dilution afterwards, I am out. And will be deducting 3,000 on line 7 of the 1040 for every year of the few years I have left.

Hoping it doesn't come to that. My fond wish is for them to quickly turn a profit. A RS split means that the profit as expressed per share will sound much greater after the RS. But we have a ways to go to turn profitable. Hopefully by the end of the year.

This is the part I have such a hard time with.  I seem to know when to buy, but difficult to decide when to book profits. Such wide swings here it is hard to use stops imo. 

You ask an interesting question. After some posters were discussing the magnitude of possible penalties for Hikma (if of course that trial went the right for us), I began to think what I would say if I were Hikma. Even if Hikma is guilty of infringing, insofar as calculating damages, could they not say, "Well, we surely aren't responsible for ALL of Amarin's lost sales". Some of the people you mentioned are obviously some of the reasons Amarin lost sales to generics. Not to mention govt programs switching people to generics. So yeah, it would be nice to know if Amarin at least sent letters warning these insurers who dropped V in their coverage that they are infringing on their CVD patents by pushing patients on to GV.

Now we did have the HealthNet suit, but the settlement details have been sealed and we have not seen any results of that settlement in terms of business.

I don't disagree with what you say, but two things need to happen.  Amarin needs to fully achieve V's potential as quick as possible and not dilute.  Always a worry that with so few shares after the RS that they might be tempted to do so, especially if they cannot achieve the business goals quick enough. 

Zip, if the trial proceeds and things begin to look like they are going our way, I bet Hikma will be squirming.

It seems like Trump wants Tik Tok operational so not sure if if we will see it shut down but here's hoping. 

In one account for some reason I had a number not evenly divisble by 20 and they have said something about not giving out partial shares so I evened it out.  I will end up just shy of 5K shares.  Still have to hope the business stabilizes and begins to increase so have plenty of but will stsrt to think about whether I need to set a new exit price.  I'm not getting any younger and have to start RMDs this year.  No question that Denner hasn't helped us one iota but I know that we had much of a choice.  Management that collected free shares and did very little to build business vs an unknown who put his own money down.  Not sure anyone could make the argument that with prior management we wouldn't be staring at delisting as well. 

I have question for you Mr Main, as our holdings and exit target have been very similar.  Before anyone stomps on me, yes I realize everything is based on market cap (sp times shares), but MrMain based on our original target, do you think we will ever see a stock price of $100 a share?  

Can you elaborate as to why you think there will be great news this week and a BO the following week?

Nuke, not to mention that if you want to make a glove look small you can kind of spread you hand somewhat to make it look like a tight fit. I remember doing such as a kid when my mother wanted to buy a glove I didn't like.

Interesting.  Have to keep an eye out. Last time Tik Toc not out for very long.  But every little bit helps

Sleven, I shouldn't have replied to your post.  I was posting that for others who were asking if and where that language was found. 

You ask an interesting question Sleven that probably many of us haven't given much thought to - I know I haven't.
An AI view:

I guess it is too much to ask of the stock gods that our sp rise over $1 before RS (RS is set in stone and I guess would happen anyway) but it is possibly (and hopefully) the stock is higher than today on April 11. Maybe we open at $15 that day?

Thanks Sleven for being on top of this and posting relevant details here.  One can support generic competition but it really has nothing to do with patent infringement.  Hope the high court understands.  I could be dead wrong but I can't really believe they would grant this petition.

MrMain, only had time to do a quick look but these sent a letter to Sesen and Carisma in Jan 2023 objecting to the terms of the merger agreement:https://www.businesswire.com/news/home/20230125005304/en/Investor-Group-Issues-Letter-to-the-Boards-of-Sesen-Bio-and-Carisma-Rejecting-Their-Apparent-Attempt-to-Purchase-Merger-Support

Then on Feb 13, 2023, the parties amended the merger agreement satifying Torok and Radoff:https://ir.carismatx.com/node/8891/ixbrl-viewer

It sure as heck feels like it. I would like to think that there isn't a leak and somehow this is just a snowball effect from people getting stopped out worried about the interim but not actual knowledge. Notice that the volume has increased that last 3 or 4 sessions. Decided to check insider action and all I see going back to Dec 24 are 3 insider purchases. I huge one from a director in late Feb. Of course if truly blinded even they are not aware of status and they could be wrong in their purchases. But when putting $5 million bucks on the line they must have some confidence.

Roadkill, good point. However, it also brings up another interesting point. Namely, that the cost of healthcare in the U.S. is so much more expensive
in the U.S. than in most of the rest of the world. Hence, some prevention here in the U.S. is worth more than elsewhere.

Just one tiny example, from Statista.com:

Laughing but wiping my brow. Reading today about how all these EU govt agencies want V a little cheaper made me think of old Jesse Livermore who talked about V indicating it would be nickels vs quarters or whatever, basically a volume play. Then my mind drifted to another stock JL touted and was very high on. I had jumped on it as well, but boy am I glad I jumped ship there. BNGO. In August 23 it was down to 60 cents and on 8/7/23 had a 1 for 10 RS, with I guess the thinking was that they wanted the stock price over $5. On the day of the RS it finished down at $4.80. Over the next year and a half the stock drifted down to 20 cents and on January 27 underwent a 1 for 60 RS finishing that day at $5.80. Today it closed at 3.25. I dodged that bullet.

Now that company no way in the same shape as AMRN. They were bleeding cash and not making any market penetration. The most important thing is not the RS, but business prospects and developments. If we can't get earnings to move in an upward trajectory, the RS won't save us. Company needs to focus on sales and earnings. Problem might be that, as Couldbebetter contends, only BP can fulfill the promise of delivering EU fully.

Thanks Sleven.  Kind of makes sure they are not doling out too much Vazkepa to people outside of the prescribing rules.  We should have something like that here preventing GV from being given to patients who are taking V for CVD.